Nahid Maspi1,2, Tooran Nayeri3,4,5, Mahmood Moosazadeh6, Shahabeddin Sarvi3,4, Mehdi Sharif7, Ahmad Daryani8,9. 1. Department of Parasitology, School of Paramedicine, Ilam University of Medical Sciences, Ilam, Iran. 2. Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran. 3. Department of Parasitology, School of Medicine, Sari Medical School, Mazandaran University of Medical Sciences, Sari, 48168-95475, Iran. 4. Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran. 5. Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran. 6. Health Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran. 7. Department of Parasitology, School of Medicine, Sari Branch, Islamic AZAD University, Sari, Iran. 8. Department of Parasitology, School of Medicine, Sari Medical School, Mazandaran University of Medical Sciences, Sari, 48168-95475, Iran. daryanii@yahoo.com. 9. Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran. daryanii@yahoo.com.
Abstract
PURPOSE: The present study aimed to analyze data available of the seroprevalence of Toxoplasma gondii (T. gondii) among camelids around the world. METHODS: The search was performed using seven international databases including Scopus, PubMed, Google Scholar, ProQuest, ScienceDirect, Web of Science, and EMBASE up to 11 October 2018. Random effects model was used to determine the pooled seroprevalence of T. gondii infection with 95% confidence intervals (CI) and analyzed data from four continents. Subgroup and meta-regression analyses were also performed according to continent and gender. RESULTS: In total, 42 studies out of 3517 published articles involving 14,542 camels from 17 countries were included for the final analyses. The global pooled seroprevalence of T. gondii infection in the Camelidae family was 28.16% (95% CI 23.64-32.68%). Besides, the highest seroprevalence rate was in Europe (49.64%) followed by Africa (37.63%), America (21.76%), and Asia (17.58%). Moreover, the overall seroprevalence rates of T. gondii infection were 22% (95% CI 10-33%) and 15% (95% CI 9-22%) for the females and males, respectively. CONCLUSION: This meta-analysis showed a high seroprevalence of T. gondii infection in camelids as these animals play an important role in the transmission cycle of this zoonotic disease.
PURPOSE: The present study aimed to analyze data available of the seroprevalence of Toxoplasma gondii (T. gondii) among camelids around the world. METHODS: The search was performed using seven international databases including Scopus, PubMed, Google Scholar, ProQuest, ScienceDirect, Web of Science, and EMBASE up to 11 October 2018. Random effects model was used to determine the pooled seroprevalence of T. gondii infection with 95% confidence intervals (CI) and analyzed data from four continents. Subgroup and meta-regression analyses were also performed according to continent and gender. RESULTS: In total, 42 studies out of 3517 published articles involving 14,542 camels from 17 countries were included for the final analyses. The global pooled seroprevalence of T. gondii infection in the Camelidae family was 28.16% (95% CI 23.64-32.68%). Besides, the highest seroprevalence rate was in Europe (49.64%) followed by Africa (37.63%), America (21.76%), and Asia (17.58%). Moreover, the overall seroprevalence rates of T. gondii infection were 22% (95% CI 10-33%) and 15% (95% CI 9-22%) for the females and males, respectively. CONCLUSION: This meta-analysis showed a high seroprevalence of T. gondii infection in camelids as these animals play an important role in the transmission cycle of this zoonotic disease.
Authors: Masoud Foroutan; Yadolah Fakhri; Seyed Mohammad Riahi; Soheil Ebrahimpour; Somayeh Namroodi; Ali Taghipour; Adel Spotin; H Ray Gamble; Ali Rostami Journal: Vet Parasitol Date: 2019-04-26 Impact factor: 2.738
Authors: Elaine Scallan; Robert M Hoekstra; Frederick J Angulo; Robert V Tauxe; Marc-Alain Widdowson; Sharon L Roy; Jeffery L Jones; Patricia M Griffin Journal: Emerg Infect Dis Date: 2011-01 Impact factor: 6.883